Related Experiment Video
Updated: Sep 5, 2025
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
13.2K
Crystallins Play a Crucial Role in Glaucoma and Promote Neuronal Cell Survival in an In Vitro Model Through
Hanhan Liu1, Katharina Bell2, Anja Herrmann3
1Department of Ophthalmology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Investigative Ophthalmology & Visual Science
|July 11, 2022
Summary
Crystallins like CRYAB, CRYBB2, and CRYGB protect retinal ganglion cells (RGCs) in aging glaucoma models. These proteins are taken up by Müller cells, stimulating neurotrophic factor release for neuroprotection.
Area of Science:
- Ophthalmology
- Neuroscience
- Cell Biology
Background:
- Glaucoma is a leading cause of irreversible blindness.
- Aging exacerbates glaucoma, leading to increased retinal ganglion cell (RGC) loss.
- Crystallins are implicated in age-related ocular diseases, but their role in glaucoma neuroprotection is unclear.
Purpose of the Study:
- To investigate the role of crystallins in aging and glaucoma.
- To explore potential neuroprotective mechanisms of crystallins in a glaucoma animal model.
Main Methods:
- Elevated intraocular pressure (IOP) induced in animal models of varying ages.
- Quantification of RGCs using immunohistochemistry.
- Proteomic analysis to identify altered crystallin expression.
- In vitro assessment of crystallin neuroprotective effects and Müller cell interactions.
Main Results:
- IOP elevation caused significant RGC loss, increasing with age.
- Age-dependent decrease in crystallin abundance (CRYAB, CRYBB2, CRYGB) correlated with RGC loss.
- CRYAB, CRYBB2, and CRYGB demonstrated significant in vitro neuroprotective effects on RGCs.
- Müller cells took up crystallins, subsequently increasing secretion of neurotrophic factors.
Conclusions:
- Age-related decline in CRYAB, CRYBB2, and CRYGB is associated with increased RGC vulnerability in glaucoma.
- CRYAB, CRYBB2, and CRYGB exhibit direct neuroprotective properties.
- Müller cell uptake and subsequent neurotrophic factor release represent a key mechanism of crystallin-mediated neuroprotection in glaucoma.
More Related Videos
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
542
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
542
01:25Glaucoma: Overview
721
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
721
01:28Angle Closure Glaucoma: Treatment
648
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
648